The Traumakine subset4 Jul 2020 09:15
Interesting reading the PATENT that Faron have for identifying the subset of patients who seem to respond much better to INFN Beta 1a treatment .
https://patents.justia.com/patent/20200199677
I had been watching an old Proactive interview with Markku in Dec 2018 , and as we all know the main finding of the post hoc analysis from Interest was the steroid issue . What was also then discovered was that in the trial , there was a subset of patients who actually responded a lot better to Traumakine ( even when they were given steroids too ) .
This subset were people who had showed the presence of single nucleotide polymorphism (SNP) rs9984273 (C/T) in subunit 2 of the interferon alpha and beta receptor (IFNAR2) in chromosome 21 .
In simple terms , that means they had a genetic trait that meant they were more receptive to IFN Beta treatment .
So Faron patented this test in 2019
It meant that in future , a quick PCR test could determine whether an ARDS sufferer was in this subset , which would mean Traumakine was definitely going to be more effective . It also meant that the patient could also be treated effectively with Traumakine concomitant with a corticosteroid.
The percentage of world population with this polymorphism varies .
30-35% of caucasians
40-45% of African origin
10% of Asians
This information was RNS'd on 5th Dec 2018 .
I must admit I hadn't paid much attention to this info , as in some ways , the negative way of looking at it was that it was only really effective in 30% odd of patients .
But in hindsight , it is actually pretty important .
In the coming years , there will be a number of drugs authorised for acute respiratory failure .
Once Traumakine is marketed , a quick PCR test when the patient is admitted will give Doctors a heads up to whether T will be the best therapy , and also , if the patient is already on steroids for whatever reason , that it is still ok to treat with T .
If the test shows a lack of this polymorphism , then T can be used , but definitely NOT steroids .
The discovery that African origin people have higher presence of this polymorphism must surely be good news for the potential use of Traumakine , as from what we know , for whatever reason , COVID has had a much bigger impact on those communities in the US and Europe , with Africa maybe just starting to catch up as the virus spreads.
To have a drug that is actually more effective in the people who seem to be hit hardest is amazing .
Also worth noting , is that with the IFN Beta 1a drugs used for MS sufferers , 50% don't actually respond . They don't know why . Again it may be a genetic marker that nobody has spotted yet .
Faron used their time wisely with the post hoc anaylsis of Interest . Markku joked that they had so much data on these patients ( 3 million data points ) , they knew how the patients thought and behaved .
https://www.youtube.com/watch?v=4VoKj6svUiw
https://cordis.europa.eu/project/id/305853
Sign In
Follow the stocks
